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A b s t r a c t  
The aim of the present study was to formulate olanzapine fast dissolving tablets (FDT). Olanzapine 
is a poorly water soluble drug that undergoes first pass metabolism in liver resulted in low oral 
bioavailability. The water solubility is enhanced by formation of co-amorphous dispersion by solvent 
evaporation under vacuum method using a polycarboxylic acid (ascorbic acid) as a coformer in two 
different molar ratios (1:1 and 1:2). The prepared systems were evaluated using differential 
scanning calorimeter (DSC), Fourier Transform Infra-Red analysis (FTIR), X-ray powder diffraction 
(XRPD), Scanning electron microscopy (SEM) and saturated solubility. The co-amorphous 
dispersion system in a molar ratio 1:2 is higher in solubility than 1:1, so it was selected for 
incorporation into FDT formulation. Compatability study between olanzapine and different tablet 
excipients including DSC and FTIR showed that the drug is compatible with the selected tablet 
excipients. Direct compression method was used in FDT formulations using different types and 
concentrations of superdisintegrants. FDTs were evaluated for weight variation, hardness, friability, 
wetting time, drug content uniformity, invitro disintegration time and invitro dissolution study. All the 
prepared FDTs were complied with the compendia standards. F3 and F8 showed lower 
disintegration time and higher percent of drug dissolved, so they were selected for stability study. 
After storage for 3 months at 30ÀC at 65% relative humidity, both formulations were physically stable 
regarding color and integrity and had only minor increases in disintegration time, drug content and 
friability after three monthsÊ storage. The results indicate that olanzapine FDT tablets may serve as a 
successful strategy for enhancing the bioavailability of olanzapine. 
Keywords: olanzapine; ascorbic acid; co-amorphous dispersion; evaporation under vacuum. 
Introduction 
Oral route is the most important and preferable route of 
administration for solid dosage forms among all routes of 
administration [1]. But it still need some advancements to be made 
because of its drawbacks related to particular class of patients 
which includes geriatric, pediatric and dysphasic patients 
associated with many medical conditions as they have difficulty in 
swallowing or chewing solid dosage forms [2,3]. Fast release 
tablets have emerged as alternative oral dosage forms. These are 
novel types of tablets that disintegrate/dissolve/ disperse in saliva 
within few seconds without the need of water or chewing [4]. The 
bioavailability of some drugs may be increased due to absorption 
of drugs in oral cavity and also due to pregastric absorption of 
saliva containing dispersed drugs that pass down into the stomach. 
Moreover, the amount of drug that is subjected to first pass 
metabolism is reduced as compared to standard tablets [4],  [5,8] 
Olanzapine or 2-methyl-4-(4-methyl-1-piperazinyl) - 10H-thieno [2, 
3-b] [1, 5] benzodiazepine {8- Firdous S,  #8} is an atypical 
antipsychotic that belongs to the thienobenzodiazepine class. 
Olanzapine is widely used in the treatment of schizophrenia and 
acute mixed or manic episode. It has been proved to be very 
efficient with no or minimal side effects. However, olanzapine 
exhibits poor water solubility and belongs to Biopharmaceutical 
Classification System (BCS) class II of drugs (low solubility and 
high permeability), highly bound to plasma protein (about 93%), 
undergoes extensive pre-systemic metabolism in the liver, resulting 
in relatively very low oral bioavailability [9,11]. Hence many trials 
were conducted to improve dissolution rate of olanzapine [12,13] 
Co-amorphous dispersions are a recent and highly effective 
approaches used to improve water solubility and bioavailability of 
poorly soluble crystalline drugs [14]. It is commonly known as multi-
component dispersions composed of an active ingredient with one 
or more neutral molecules known as co-formers [15]. Amorphous 
solids are non-crystalline materials in which the arrangement of the 
component atoms does not have a long-range order. They provide 
higher dissolution rates, also considered suitable and easy 
alternatives to co-crystals which often need complicated methods 
for its preparation and quantification, in addition to the physical 
instability and possible formation of polymorphs and hydrate [16]. 
Co-amorphous dispersions can be prepared from solutions of the 
crystalline drugs especially when rapid co-precipitation is pursued 
using carboxylic acids as plasticizing agents [17,19], neutral 
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molecules capable of forming strong H-bonding such as saccharin 
[20] or nicotinamide [21]or small molecular mass amino acids [22]. 
Plasticized co-amorphous dispersions prepared from crystalline 
drugs with polycarboxylic acids are rare [23]. Therefore, the aim of 
the present work is to enhance solubility of olanzapine before 
integration into tablet formulations via formation of stable 
olanzapine co-amorphous dispersions with polycarboxylic acids 
using solvent evaporation under vacuum method followed by 
incorporation into different tablet formulations. This lead to 
maximization of the oramucosal absorption of olanzapine which in 
turn improve its therapeutic efficacy [24] 
Materials and Methods 
Materials  
Olanzapine was obtained as a free sample from the Egyptian 
Pharmaceutical Industries Company (EPICO, Egypt); 
Microcrystalline cellulose (Avicel® PH102) provided by (FMC Corp., 
Pennsylvania, USA); Emcosoy (RS PHARMA GmbH & Co. KG, 
Rosenberg, Germany);  Pharmaburst® 500 (SPI Pharma, USA); 
Granular mannitol, Sodium stearyl fumarate (SPI Pharma, USA); 
Sodium starch glycolate (Explotab®) provided by (FMC Corp., 
Philadelphia, USA); Disodium hydrogen phosphate, Potassium 
dihydrogen orthophosphate (Sigma-Aldrich, Germany); Cross 
linked polyvinyl pyrrolidine (Crospovidone®), Na Saccharine (Fluka, 
Germany); anhydrous ascorbic acid was purchased from El Nasr, 
Chemical and Pharmaceutical Company (Egypt); Ethanol (95 %) 
and acetone were purchased from El-Gomhoria Company (Egypt). 
Enhancement the solubility of olanzapine through 
formation of olanzapine/ascorbic acid co-amorphous 
dispersions  
The calculated equivalent amounts of anhydrous ascorbic acid 
(coformer) according to the selected molar ratios (Table I), were 
dissolved in ethanol,95% (10 mls), The weighted amount of 
olanzapine (200 mg) was dissolved in acetone (10 ml)and then 
mixed with the ethanolic solution of ascorbic acid in a rotary 
evaporation flask. 
The flask contents were sonicated for 10 min in a water bath 
sonicator (Ultrasonic Cleaner Model 57 H, Ney Instruments Co. 
Ltd, USA) until all contents were completely dissolved. The 
resulting solution was evaporated under vacuum (0.25 MPa) using 
a rotary evaporator (Barloworld Scientific Ltd., UK). The water 
bath temperature was kept at 50ĈC. After complete dryness, the 
collected mass was pulverized and passed through sieve 
number 60 (250 øm apertures), then kept in a desiccator until 
further examination. 
Solid state characterization of olanzapine/ascorbic acid 
co-amorphous dispersions 
Differential scanning calorimetry (DSC) 
DSC analysis of pure olanzapine, ascorbic acid, drug- ascorbic 
acid physical mixture (PM) and the prepared co-amorphous 
dispersion (CD) formulations (5 mg each) were carried out using 
DSC (DSC-50, Shimadzu, Kyoto, Japan). The instrument was 
calibrated using purified Indium (99.99%). Samples (5mg) were 
sealed in a flat bottomed aluminum pan. The pan was placed in the 
DSC instrument and scanned between 30 and 300/C at a rate of 
10ÀC/min.  
Fourier Transform Infra-Red analysis (FTIR) 
Each sample (5mg) of olanzapine, coformer, drug-coformer PM 
and prepared dispersions were individually mixed with 100 mg dry 
potassium bromide. The powder mixtures were compressed into 
discs under a pressure of 10,000 to 15,000 pounds per square 
inch. The infrared spectrum was determined at a scanning range of 
400-4000 cm-1 using a Fourier Transform Infra-red instrument 
(Shimadzu IR-345, Japan). 
X-ray powder diffraction (XRPD) 
Samples of olanzapine, coformer, drug-coformer PM as well as the 
solid dispersion formulations were subject to X-ray diffraction 
analysis. A Shimadzu XRD-6000 X-ray powder diffractometer 
coupled with a standard Cu sealed X-ray tube with voltage, current 
(40 kV and 30 mA) was used to characterize the amorphous or 
crystalline state of formulations. Data collection was performed at 
2- theta of 5 - 80Ĉ in steps of 0.05 and scanning speed of 0.5 per 
step. 
Scanning electron microscopy (SEM) 
The morphology of the prepared dispersions was examined using 
scanning electron microscopy (JEOL-JSM-6510LA, JEOL, Japan). 
Few specks from each formulation were placed on the carbon 
stubs and then coated using a gold sputter followed by 
microscopical scanning. 
Saturated solubility 
Saturated solubility measurements of the prepared CDs in 
comparison to the drug were carried out by adding known excess 
amount of each formula to water (10 mL) and was kept in a 
shaking water bath (37ÀC) for 24 h. The samples were left for 12 h 
to equilibrate then were filtrated using membrane filter (0.45øm). 
The filtrate was analyzed spectrophotometrically (Shimadzu, 
model-UV-1601 PC (s), Kyeto, Japan) at λ max 253nm.  
Compatibility Studies of olanzapine with different 
excipients used in tablets formulations 
The physical mixtures of the drug with the different excipients used 
in tablet preparation in the ratio of 1:1 were subjected to the 
following: 
Visual examination 
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Samples of physical mixtures of the drug with the different 
excipients were subjected to visual examination either fresh or after 
storage for two weeks at 60 ÀC. Samples were withdrawn daily 
during the subsequent period. The withdrawn samples were tested 
visually for any changes in appearance such as; discoloration, 
caking and liquefaction of clumps. 
Differential Scanning Calorimetry (DSC) 
DSC of the used excipients; namely sodium starch glycolate 
(SSG), emcosoy, microcrystalline cellulose (MCC), granular 
mannitol, crospovidone (CP), Na Saccharine, pharmaburst® 500, 
sodium stearyl fumarate (SSF) and their physical mixtures were 
studied.  
Fourier Transform Infra-Red analysis (FTIR) 
Infrared spectra of all materials used in preparing fast dissolving 
tablets were studied. 
Formulation of olanzapine fast dissolving tablets (FDT) 
by direct compression method 
A total number of eighteen formulations were prepared by direct 
compression. All ingredients were passed through 60- mesh sieve. 
The calculated amount of drug CD (1:2 molar ratio), 
superdisintegrant (emcosoy, SSG, or crospovidone), pharmaburst, 
Na Saccharine and MCC or granular mannitol were well mixed 
using morter and pestle then the calculated amount of sodium 
stearyl fumarate was added and mixed thoroughly. Tablets were 
compressed into 120 mg tablets using single punch machine of 8 
mm flat punch and die set (Model TDP, SHANGHAI TIANHE, 
China). 
Quality control tests of olanzapine FDTTablet weight 
and weight variation 
Weight variation test was done by weighing twenty tablets 
individually then calculating the average weight and comparing the 
individual tablet weight to the average one. 
Uniformity of tablet diameter and thickness 
The diameter and thickness of ten tablets were measured using 
Vernier caliber (Shanghai, China) at two different positions. The 
average value was then calculated. 
Tablet Hardness 
Ten tablets from each formula were tested for their hardness using 
hardness tester (Dr-Schleuniger, pharmaton, USA) then the mean 
hardness in kg of each formula was determined.  
Friability 
The percentage friability was evaluated using a tablet friabilator 
(Pharma Test, Germany). Pre-weighted sample of tablets was 
placed in the drum, which was then rotated at 25 r.p.m for a period 
of four minutes. Tablets were dusted and reweighed and the 
percentage loss in weight was calculated.  
Wetting time 
Five circular filter papers of 10 cm diameter are placed in a 
petridish with a 10 cm diameter. Ten milliliters of water-soluble dye 
(eosin) solution 5% (w/v) is added to petridish. A tablet is carefully 
placed on the surface of the filter paper. The time required for 
water to reach upper surface of the tablet is noted as the wetting 
time. 
Drug Content 
Ten tablets were used in this test, where each one was crushed 
and transferred into 100 ml volumetric flask. The flasks were 
brought to volume by phosphate buffer pH 6.8. The flasks were 
placed onto a sonicator till complete dissolution; 1ml of the solution 
was filtered through a millipore filter of 0.45 øm pore size (Millpore, 
Milford, USA) then introduced into 25 ml volumetric flask which was 
completed to volume by phosphate buffer. The absorbance of the 
solution was measured spectrophotometrically against buffer as a 
blank at 253 nm. 
In-vitro disintegration time 
The disintegration time of fast dissolving tablets was performed 
using the compendial disintegration test apparatus (Hanson 
Research, Chatsworth, USA). In this experiment, 900 ml of 
phosphate buffer pH=6.8 kept at 37 μ 1ĈC was used as the 
disintegration medium and the basket was raised and lowered at a 
constant frequency of 30μ2 cycles/min. The test results were 
presented as the average of six determinations. The time of total 
disintegration was considered to be achieved when no tablet 
fragments remain on the screen.  
In-vitro dissolution studies 
The in-vitro dissolution of all prepared formulations was 
investigated using USP type II dissolution apparatus (Hanson 
Research, Chatsworth, USA) at 50 rpm with temperature of 
37μ0.5ÀC and 900 ml of phosphate buffer pH 6.8. At specified time 
intervals (1, 3, 5, 7, 10, 15, 20, 25 and 30 min); aliquots of 5 ml of 
dissolution medium was withdrawn and replaced with an equal 
volume of medium to maintain a constant total volume. Samples 
were then filtered through 0.45 øm Millipore filter and assayed for 
drug content spectrophotometrically at 253 nm. Cumulative percent 
of drug dissolved in the preparations was calculated using 
calibration equation. Dissolution efficiency % (DE%) and initial 
dissolution rate (IDR) were measured for each formula. 
Effect of ageing 
Formulations F3 and F8 was stored for 3 months at 30ÀC at 65% 
relative humidity. The effect of ageing was studied by measuring 
both the in vitro drug release and disintegration time. 
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Result and Discussion 
Solid state characterization of the prepared 
olanzapine/ascorbic acid co-amorphous dispersions 
Differential scanning calorimetry (DSC) 
DSC thermograms of the drug, physical mixture and co-amorphous 
dispersions systems are shown in figure 1. It is clear from the 
figure that the thermogram of the drug was that of a highly 
crystalline drug with a sharp endothermic peak at 194.01ÀC (’H = 
126.83 J/g) corresponding to its melting point. The thermogram of 
ascorbic acid showed a melting endothermic peak at 191.24ÀC. 
Thermograms of the CDs (containing ascorbic acid at 1 and 2 
molar ratios, respectively) showed broad peaks with complete 
disappearance of characteristic melting endotherms of parent 
components suggesting formation of co-amorphous phases. 
 
Figure. (1): DSC thermogram of  a) pure olanzapine, b) anhydrous ascorbic acid, c) olanzapine-ascorbic acid PM d) olanzapine-
ascorbic acid CD 1:1 molar ratio, e)  olanzapine-ascorbic acid CD 1:2 molar ratio. 
Fourier Transform Infra-Red analysis (FTIR) 
The FT-IR spectra of OLZ, physical mixtures (1:1) and CDs are 
presented in figure 2. Pure OLZ showed characteristic absorptions 
at 3217 cmă1 (NH stretching), 2929 , 2836, and 2791cmă1 (CăH 
stretching), 1586 cmă1 (C=C stretching), 1461 cmă1 (C=N 
stretching) and 1283 cmă1 CăN stretching) [25]. The FTIR spectra 
of ascorbic acid indicated a characteristic peak at 1754 cmî1 which 
is attributed to the C=O stretching vibration in carboxyl groups. The 
characteristic peaks of pure OLZ were found to be present in the 
spectra of PM. Formulations CD1 and CD2 showed shortening or 
disappearance of certain peaks of olanzapine (C-H stretching and 
C=N stretching), Broadened shallow peak of N-H stretching shifting 
to 3394 cm-1 instead of 3217 cm-1. These results suggest that the 
interaction between olanzapine and ascorbic acid most probably 
through H bonding. 
 
 








Figure. (2): FTIR spectra of  a) pure olanzapine, b) anhydrous ascorbic acid, c) olanzapine-ascorbic acid PM d) olanzapine-ascorbic acid CD 1:1 
molar ratio, e)  olanzapine-ascorbic acid CD 1:2 molar ratio. 
 
X-ray powder diffraction (XRPD) 
As shown in figure 3, the  diffraction spectrum of pure olanzapine 
show that the drug was crystalline in nature as demonstrated by 
characteristic intense peaks at 2 theta 8.67, 17.09, 19.87, 21.05, 
21.54, and 23.95À. These results are in good agreement with what 
was reported for olanzapine in the literature {25- AJIT,  #25}. The 
XRD pattern for ascorbic acid also showed multiple sharp 
characteristic peaks at 2 theta 10.63, 15.89, 17.59, 25.33, 27.25, 
28.19, 30.18, and 34.85À. The XRD spectra of the drug-ascorbic 
acid PM showed sharp characteristic peaks at 2 theta 8.65, 10.47, 
19.88, 21.03, 25.21, 26.83, and 29.97 that indicate compatibility 
between drug and ascorbic acid. The diffraction spectrum of the 
co-amorphous dispersions demonstrated disappearance of the 
characteristic peaks of both olanzapine and ascorbic acid and 
appearance of amorphous halo. The results of DSC, IR, and XRPD 
strongly suggest that amorphous systems were obtained through 
H-bonding interactions between the drug and ascorbic acid. 
 
 
Figure. (3): X-ray diffractograms of a) pure olanzapine, b) anhydrous ascorbic acid, c) olanzapine-ascorbic acid PM d) olanzapine-
ascorbic acid CD 1:1 molar ratio, e) olanzapine-ascorbic acid CD 1:2 molar ratio. 
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Scanning electron microscopy (SEM) 
Figure (4, A) is a photomicrograph of olanzapine powder; the figure 
clearly illustrates the crystalline nature of the drug that was 
previously proven by the x-ray diffraction test. 
Figure (4, B) show the crystals of the drug mixed with the large 
crystals of ascorbic acid, while the micrographs of the co-
amorphous systems (Figure. 4, C, D) show a matrix in which no 




Figure. 4: SEM microphotographs of (A) pure olanzapine (B) olanzapine-ascorbic acid PM d) olanzapine-ascorbic acid CD 1:1 molar ratio, e) 
olanzapine-ascorbic acid CD 1:2 molar ratio. 
 
Saturated solubility  
All the test samples showed an increase in drug solubility over 
crystalline olanzapine (Table 1). the drug-coformer molar ratio 1:2 
enhanced solubility greater than that of 1:1, so it was selected for 
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Table I. Composition of olanzapine-ascorbic acid co-amorphous dispersions and their saturated solubility  
Compatibility Studies of olanzapine with different 
excipients 
Neither the fresh mixtures nor the stored ones showed any change 
in color or appearance throughout the storage period. The absence 
of such signs is a good preliminary step of physical stability. 
The DSC (Figure. 5, 6) and IR spectra of olanzapine (Figure. 7, 8) 
in mixtures with all excipients showed the same characteristic 
bands of the drug in the same regions and the same ranges, 
indicating that there was no interaction between the drug and any 
of the excipients used. Also, there is no remarkable change 
between the fresh and the stored mixtures indicating the stability of 
the mixtures. 
 
Figure. (5): DSC thermogram of  olanzapine and different tablet excipients (fresh and stored) 








Figure. (6): DSC thermogram of olanzapine and different tablet excipients (fresh and stored) 
 
 
Figure. (7): FTIR of olanzapine and different tablet excipients (fresh and stored) 
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Figure. (8): FTIR of olanzapine and different tablet excipients (fresh and stored). 
Quality control tests of olanzapine FDT 
As shown in table 3,     all the prepared olanzapine FDT formulae 
complied with the compendia standards for the weight variation 
and content uniformity tests (all tablet formulae were found to 
conform to pharmacopoeial limit 85% - 115%) of the label claim. 
The prepared tablets showed a uniformity of diameter and 
thickness. 
All olanzapine FDT formulae showed hardness values ranged from 
2.75 to 4.12 kilograms, with standard deviation less than 2%.     A 
significant strength of FDT is difficult to achieve due to the 
specialized processes and ingredients used in the manufacturing. 
The limit of crushing strength for FDT is usually kept in a lower 
range to facilitate early disintegration in the mouth {26- Bandari S.,  
#26}. According to compendial standards, the prepared formulae 
comply with the friability test if the weight loss during the friability 
test was less than 1%; in addition, the tablets should not break or 
show any capping or cracking during the test [26]. All FDT 
formulations showed rapid wetting time ranging from 9 to 31 
seconds. These results correlated well with disintegration testing 
results. 
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Table (2): Composition of different olanzapine fast dissolving tablets formulae prepared by direct compression method 
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     * Olanzapine/ascorbic acid co-amourphous dispersion 1:2 molar ratio 
     ** All FDT contain Pharmaburst (20%) 24mg, SSF (1%) 1.2mg, Na saccharine (1%) 1.2mg 
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Figure. (10): Histogram of initial dissolution rate (IDR), and dissolution efficiency (DE %) of pure olanzapine (Olanz) and the FDT formulations 
 
Stability of stored FDT tablets 
Both formulations (F3 and F8) were physically stable regarding 
color and integrity and had only minor increases in disintegration 
time, drug content and friability after three monthsÊ storage. 
Conclusion 
From the dissolution data of all formulations developed, solubility of 
olanzapine, a poorly water soluble drug was enhanced by the co-
amorphous dispersion technique using anhydrous ascorbic acid as 
a coformer. This effect may be due to formation of new phases 
between drug and the conformer through H-bonding, thus facilitate 
conversion of crystalline drug to flexible co-amorphous system 
characterized by enhanced solubility and percentage dissolution. 
Finally, it could be concluded that using olanzapine-ascorbic acid 
co-amorphous system in a molar ratio 1:2 in FDT formulations in 
presence of a superdisintegrant resulted in fast disintegration time 
and rapid dissolution rate which are expected to increase oral 
bioavailability of olanzapine. 
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